烟酰胺激活NAMPT/NAD+代谢轴调控程序性死亡配体1表达促进宫颈癌恶性进展的作用机制
收稿日期: 2025-12-13
网络出版日期: 2026-04-29
基金资助
国家自然科学基金项目(82473350);无锡市科技发展资金项目(K20241012);无锡市科协软课题项目(KX-25-C282)
Nicotinamide promotes cervical cancer progression via the NAMPT/NAD+ axis-mediated regulation of PD-L1
Received date: 2025-12-13
Online published: 2026-04-29
目的 探讨烟酰胺（nicotinamide，NAM）通过激活NAMPT/NAD?代谢轴调控程序性死亡配体1（programmed death-ligand 1，PD-L1）表达、并促进宫颈癌恶性进展的作用机制。 方法 利用30例配对宫颈癌及癌旁组织分析烟酰胺磷酸核糖基转移酶（nicotinamide phosphoribosyltransferase，NAMPT）和PD-L1在宫颈癌中的表达；qRT-PCR、Western blot检测NAMPT、PD-L1转录及蛋白表达水平；采用NAMPT抑制剂（FK866）抑制NAMPT表达，验证其在代谢—免疫调控中的关键作用；通过CCK-8法、克隆形成实验、划痕实验、Transwell实验评估宫颈癌细胞增殖、迁移及侵袭能力。 结果 临床样本验证显示，NAMPT、PD-L1在宫颈癌组织中高表达（P < 0.05）；体外细胞实验示，外源性NAM处理可浓度依赖性上调宫颈癌细胞中NAMPT、PD-L1的表达（P < 0.05），并显著增强其增殖、迁移及侵袭能力（P < 0.05）；而FK866可特异性阻断NAM的上述效应（P < 0.05），且逆转PD-L1的上调表达。 结论 NAM激活NAMPT/NAD?代谢轴，上调PD-L1表达并促进肿瘤细胞恶性生物学行为；二者在该轴调控下同步变化，提示存在潜在内在调控关联。
关键词： 宫颈癌; NAMPT/NAD?; 程序性死亡配体1; 烟酰胺; 肿瘤细胞恶性表型
唐倩云 , 陆欣怡 , 陈钰 , 许涵洁 , 陈道桢 . 烟酰胺激活NAMPT/NAD+代谢轴调控程序性死亡配体1表达促进宫颈癌恶性进展的作用机制[J]. 实用医学杂志, 2026 , 42(9) : 1536 -1544 . DOI: 10.3969/j.issn.1006-5725.2026.09.007
Objective To investigate the role and underlying mechanism of nicotinamide （NAM） in promoting cervical cancer malignant progression and regulating PD-L1 expression via activation of the NAMPT/NAD? metabolic axis. Methods Thirty pairs of cervical cancer tissues and adjacent normal tissues were collected to analyze the expression levels of nicotinamide phosphoribosyltransferase （NAMPT） and programmed death-ligand 1 （PD-L1）. Quantitative real-time polymerase chain reaction （qRT-PCR） and Western blotting were employed to quantify their transcriptional and protein levels， respectively. The specific NAMPT inhibitor FK866 was utilized to block NAMPT activity and verify its pivotal role in metabolic-immune regulation. Furthermore， CCK-8， colony formation， wound healing， and Transwell assays were conducted to evaluate cervical cancer cell proliferation， migration， and invasion capacities. Results Clinical sample analysis revealed that both NAMPT and PD-L1 were significantly upregulated in cervical cancer tissues compared to adjacent normal tissues （P < 0.05）. In vitro experiments demonstrated that exogenous NAM treatment upregulated NAMPT and PD-L1 expression in cervical cancer cells in a concentration-dependent manner （P < 0.05）， while significantly enhancing cell proliferation， migration， and invasion （P < 0.05）. Conversely， treatment with FK866 specifically abrogated these NAM-induced effects （P < 0.05） and reversed the upregulation of PD-L1. Conclusion NAM activates the NAMPT/NAD+ metabolic axis to upregulate PD-L1 expression， thereby promoting the malignant biological behaviors of cervical cancer cells. The coordinated upregulation of NAMPT and PD-L1 suggests an intrinsic regulatory link within this metabolic-immune axis.
Key words： cervical cancer; NAMPT/NAD+; PD-L1; nicotinamide; malignant phenotype of tumor cells
| [1] | HAN B， ZHENG R， ZENG H， et al. Cancer incidence and mortality in China， 2022［J］.J Natl Cancer Cent， 2024，4（1）：47-53.doi：10.1016/j.jncc.2024.01.006 . |
| [2] | TEWARI K S， COLOMBO N， MONK B J， et al. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent， Recurrent， or Metastatic Cervical Cancer： Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial［J］.JAMA Oncol， 2024，10（2）：185-192.doi：10.1001/jamaoncol.2023.5410 . |
| [3] | KRUGER S， ILMER M， KOBOLD S， et al. Advances in cancer immunotherapy 2019-latest trends［J］.J Exp Clin Cancer Res， 2019，38（1）：268.doi：10.1186/s13046-019-1266-0 . |
| [4] | JEONG H， KOH J， KIM S， et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer［J］.J Immunother Cancer， 2025，13（3）：e010612.doi：10.1136/jitc-2024-010612 . |
| [5] | 张雨峤， 梅伟健.免疫检查点抑制剂治疗实体瘤的标志性成果［J］.实用医学杂志， 2024，40（2）： 272-277.doi：10.3969/j.issn.1006-5725.2024.02.025 . |
| [6] | GE Y， ZHANG Y， ZHAO K N， et al. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer［J］.Drug Des Devel Ther， 2022，16（1）：3055-3070.doi：10.2147/DDDT.S374672 . |
| [7] | WANG S， LI J， XIE J， et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway［J］.Oncogene， 2018，37（30）：4164-4180.doi：10.1038/s41388-018-0252-x . |
| [8] | NAVAS L E， CARNERO A. NAD+ metabolism， stemness， the immune response， and cancer［J］.Signal Transduct Target Ther， 2021，6（1）：1-2.doi：10.1038/s41392-020-00354-w . |
| [9] | CHIANG Y F， HUANG K C， HUANG T C， et al. Regulatory roles of NAMPT and NAD+metabolism in uterine leiomyoma progression： Implications for ECM accumulation， stemness， and microenvironment［J］.Redox Biol， 2024，78：103411.doi：10.1016/j.redox.2024.103411 . |
| [10] | HONG S M， LEE A Y， KIM B J， et al.NAMPT-Driven M2 Polarization of Tumor-Associated Macrophages Leads to an Immunosuppressive Microenvironment in Colorectal Cancer［J］.Adv Sci （Weinh）， 2024，11（14）：e2303177.doi：10.1002/advs.202303177 . |
| [11] | KUDO K， GREER Y E， YOSHIDA T， et al. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer［J］.Cancer Gene Ther， 2024，31（5）：721-735.doi：10.1038/s41417-024-00748-w . |
| [12] | ZHOU G， QIN G， ZHANG Z， et al. Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma［J］.Front Immunol， 2023，14（1）：1283792.doi：10.3389/fimmu.2023.1283792 . |
| [13] | YANG Y， WANG Z， HE M， et al. NAD+ biosynthesis metabolism predicts prognosis and indicates immune microenvironment for breast cancer［J］.Pathol Oncol Res， 2023，29（1）：1610956.doi：10.3389/pore.2023.1610956 . |
| [14] | LV H， LV G， CHEN C， et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion［J］.Cell Metab， 2021，33（1）：110-127.e5.doi：10.1016/j.cmet.2020.10.021 . |
| [15] | MINAFò Y A， ANTONINI D， DELLAMBRA E. NAD+ Metabolism-Related Gene Profile Can Be a Relevant Source of Squamous Cell Carcinoma Biomarkers［J］.Cancers （Basel）， 2024，16（2）：309.doi：10.3390/cancers16020309 . |
| [16] | CHEN K C， DHAR T， CHEN C R， et al. Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity［J］.Biochim Biophys Acta Mol Basis Dis， 2024，1870（4）：167106.doi：10.1016/j.bbadis.2024.167106 . |
| [17] | DENG Y， HU B， MIAO Y， et al. A Nicotinamide Phosphoribosyltransferase Inhibitor， FK866， Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1［J］.Front Oncol， 2022，2（1）：836257.doi：10.3389/fonc.2022.836257 . |
| [18] | LUCENA-CACACE A， OTERO-ALBIOL D， JIMéNEZ-GARCíA M P， et al. NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP［J］.Clin Cancer Res， 2018，24（5）：1202-1215. doi：10.1158/1078-0432.CCR-17-2575 . |
| [19] | HE X L， GUO H J， LEI Y R， et al. NAMPT promotes the malignant progression of HBV-associated hepatocellular carcinoma through activation of SREBP1-mediated lipogenesis［J］.FASEB J， 2024，38（2）：e23444.doi：10.1096/fj.202300070RRR . |
| [20] | 孙良璋， 徐正水， 张丹杰， 等. NAMPT及高糖高胰岛素微环境对人顺铂耐药肺癌细胞株增殖和转移的影响［J］.现代生物医学进展， 2023，23（24）：4620-4626+4619.doi：10.13241/j.cnki.pmb.2023.24.004 . |
| [21] | 王艳辉，柳雅慧，任丽.NAMPT基因对肾癌细胞增殖和凋亡的影响及其机制研究［J］.天津医科大学学报， 2021，27（4）：343-348+378.doi：10.20135/j.issn.1006-8147.2021.04.006 . |
| [22] | GAO P， ZUO C， YUAN W， et al. Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer［J］.Signal Transduct Target Ther， 2025，10（1）：313.doi：10.1038/s41392-025-02390-w . |
| [23] | 李雯， 黄海生， 黄斌， 等. 程序性死亡配体-1、人表皮生长因子受体-2在浸润性尿路上皮癌中的表达相关性及对预后影响［J］.实用医学杂志， 2026， 42（2）： 194-200.doi：10.3969/j.issn.1006-5725.2026.02.004 . |
| [24] | HU T， WAN X， WU H， et al.Predictive values of PD-L1 expression for survival outcomes in patients with cervical cancer： A systematic review and meta-analysis［J］.Ginekol Pol， 2022，93（10）：767-774.doi：10.5603/GP.a2022.0071 . |
/
| 〈 |
|
〉 |